Literature DB >> 29958801

Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy.

Jinyang Li1, Katelyn T Byrne2, Fangxue Yan1, Taiji Yamazoe1, Zeyu Chen3, Timour Baslan4, Lee P Richman1, Jeffrey H Lin1, Yu H Sun5, Andrew J Rech6, David Balli1, Ceire A Hay7, Yogev Sela1, Allyson J Merrell1, Shannon M Liudahl8, Naomi Gordon1, Robert J Norgard1, Salina Yuan1, Sixiang Yu1, Timothy Chao1, Shuai Ye1, T S Karin Eisinger-Mathason1, Robert B Faryabi9, John W Tobias10, Scott W Lowe11, Lisa M Coussens8, E John Wherry12, Robert H Vonderheide13, Ben Z Stanger14.   

Abstract

The biological and functional heterogeneity between tumors-both across and within cancer types-poses a challenge for immunotherapy. To understand the factors underlying tumor immune heterogeneity and immunotherapy sensitivity, we established a library of congenic tumor cell clones from an autochthonous mouse model of pancreatic adenocarcinoma. These clones generated tumors that recapitulated T cell-inflamed and non-T-cell-inflamed tumor microenvironments upon implantation in immunocompetent mice, with distinct patterns of infiltration by immune cell subsets. Co-injecting tumor cell clones revealed the non-T-cell-inflamed phenotype is dominant and that both quantitative and qualitative features of intratumoral CD8+ T cells determine response to therapy. Transcriptomic and epigenetic analyses revealed tumor-cell-intrinsic production of the chemokine CXCL1 as a determinant of the non-T-cell-inflamed microenvironment, and ablation of CXCL1 promoted T cell infiltration and sensitivity to a combination immunotherapy regimen. Thus, tumor cell-intrinsic factors shape the tumor immune microenvironment and influence the outcome of immunotherapy.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29958801      PMCID: PMC6707727          DOI: 10.1016/j.immuni.2018.06.006

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   43.474


  56 in total

1.  An immune-active tumor microenvironment favors clinical response to ipilimumab.

Authors:  Rui-Ru Ji; Scott D Chasalow; Lisu Wang; Omid Hamid; Henrik Schmidt; John Cogswell; Suresh Alaparthy; David Berman; Maria Jure-Kunkel; Nathan O Siemers; Jeffrey R Jackson; Vafa Shahabi
Journal:  Cancer Immunol Immunother       Date:  2011-12-07       Impact factor: 6.968

2.  BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors:  Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades
Journal:  Cell       Date:  2011-09-01       Impact factor: 41.582

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

4.  Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.

Authors:  Richard E Royal; Catherine Levy; Keli Turner; Aarti Mathur; Marybeth Hughes; Udai S Kammula; Richard M Sherry; Suzanne L Topalian; James C Yang; Israel Lowy; Steven A Rosenberg
Journal:  J Immunother       Date:  2010-10       Impact factor: 4.456

5.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.

Authors:  Sunil R Hingorani; Lifu Wang; Asha S Multani; Chelsea Combs; Therese B Deramaudt; Ralph H Hruban; Anil K Rustgi; Sandy Chang; David A Tuveson
Journal:  Cancer Cell       Date:  2005-05       Impact factor: 31.743

6.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.

Authors:  Julien Fourcade; Zhaojun Sun; Mourad Benallaoua; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; John M Kirkwood; Vijay Kuchroo; Hassane M Zarour
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

7.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

8.  CD103+ pulmonary dendritic cells preferentially acquire and present apoptotic cell-associated antigen.

Authors:  A Nicole Desch; Gwendalyn J Randolph; Kenneth Murphy; Emmanuel L Gautier; Ross M Kedl; Mireille H Lahoud; Irina Caminschi; Ken Shortman; Peter M Henson; Claudia V Jakubzick
Journal:  J Exp Med       Date:  2011-08-22       Impact factor: 14.307

9.  Fast and accurate long-read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2010-01-15       Impact factor: 6.937

10.  Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity.

Authors:  Kai Hildner; Brian T Edelson; Whitney E Purtha; Mark Diamond; Hirokazu Matsushita; Masako Kohyama; Boris Calderon; Barbara U Schraml; Emil R Unanue; Michael S Diamond; Robert D Schreiber; Theresa L Murphy; Kenneth M Murphy
Journal:  Science       Date:  2008-11-14       Impact factor: 47.728

View more
  227 in total

Review 1.  How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.

Authors:  Jinyang Li; Ben Z Stanger
Journal:  Cancer Res       Date:  2020-06-18       Impact factor: 12.701

Review 2.  The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies.

Authors:  Andres Garcia-Sampedro; Gabriella Gaggia; Alexander Ney; Ismahan Mahamed; Pilar Acedo
Journal:  J Clin Med       Date:  2021-02-03       Impact factor: 4.241

3.  Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model.

Authors:  Jayanth S Shankara Narayanan; Partha Ray; Tomoko Hayashi; Thomas C Whisenant; Diego Vicente; Dennis A Carson; Aaron M Miller; Stephen P Schoenberger; Rebekah R White
Journal:  Cancer Immunol Res       Date:  2019-08-13       Impact factor: 11.151

Review 4.  Cellular determinants and therapeutic implications of inflammation in pancreatic cancer.

Authors:  Meredith L Stone; Gregory L Beatty
Journal:  Pharmacol Ther       Date:  2019-05-31       Impact factor: 12.310

Review 5.  Treatment resistance in diffuse large B-cell lymphoma.

Authors:  Michael Y He; Robert Kridel
Journal:  Leukemia       Date:  2021-05-20       Impact factor: 11.528

6.  IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.

Authors:  Giulia Biffi; Tobiloba E Oni; Benjamin Spielman; Yuan Hao; Ela Elyada; Youngkyu Park; Jonathan Preall; David A Tuveson
Journal:  Cancer Discov       Date:  2018-10-26       Impact factor: 39.397

7.  The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment.

Authors:  Gurkan Mollaoglu; Alex Jones; Sarah J Wait; Anandaroop Mukhopadhyay; Sangmin Jeong; Rahul Arya; Soledad A Camolotto; Timothy L Mosbruger; Chris J Stubben; Christopher J Conley; Arjun Bhutkar; Jeffery M Vahrenkamp; Kristofer C Berrett; Melissa H Cessna; Thomas E Lane; Benjamin L Witt; Mohamed E Salama; Jason Gertz; Kevin B Jones; Eric L Snyder; Trudy G Oliver
Journal:  Immunity       Date:  2018-10-16       Impact factor: 31.745

8.  Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia.

Authors:  Jayakumar Vadakekolathu; Mark D Minden; Tressa Hood; Sarah E Church; Stephen Reeder; Heidi Altmann; Amy H Sullivan; Elena J Viboch; Tasleema Patel; Narmin Ibrahimova; Sarah E Warren; Andrea Arruda; Yan Liang; Thomas H Smith; Gemma A Foulds; Michael D Bailey; James Gowen-MacDonald; John Muth; Marc Schmitz; Alessandra Cesano; A Graham Pockley; Peter J M Valk; Bob Löwenberg; Martin Bornhäuser; Sarah K Tasian; Michael P Rettig; Jan K Davidson-Moncada; John F DiPersio; Sergio Rutella
Journal:  Sci Transl Med       Date:  2020-06-03       Impact factor: 17.956

9.  Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.

Authors:  Lillian Sun; Paul E Clavijo; Yvette Robbins; Priya Patel; Jay Friedman; Sarah Greene; Rita Das; Chris Silvin; Carter Van Waes; Lucas A Horn; Jeffrey Schlom; Claudia Palena; Dean Maeda; John Zebala; Clint T Allen
Journal:  JCI Insight       Date:  2019-04-04

10.  Infiltration of CD8+ T cells into tumor cell clusters in triple-negative breast cancer.

Authors:  Xuefei Li; Tina Gruosso; Dongmei Zuo; Atilla Omeroglu; Sarkis Meterissian; Marie-Christine Guiot; Adam Salazar; Morag Park; Herbert Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.